Canada joins EU on the biosimilars train
This article was originally published in The Gold Sheet
Executive SummaryHealth Canada has issued a "Draft Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs). The document guides sponsors on information and regulatory requirements for subsequent entry biologic products in Canada. The concept of a SEB applies to all biologic drug submissions in which the sponsor would, based on demonstrated similarity to a reference biologic product, rely in part on publicly available information from a previously approved biologic drug in order to present a reduced clinical package as part of the submission. The EU has allowed approval of biosimilar products since 2005. Biosimilar legislation is currently pending in the U.S. and is being held up by legislators' concerns on extended data exclusivity for brand companies and coming to terms with what should constitute a biosimilar drug
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.